Sabrina Schnur

Ms. Sabrina Schnur

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SSSabrina Schnur
Sabrina Schnur
FHFabian Hans
Fabian Hans
ADAnnika Dehne
Annika Dehne
JOJanina Osti
Janina Osti
MSMalte-Ole Schneemann
Malte-Ole Schneemann
MHMarius Hittinger
Marius Hittinger
Complementary and alternative medicine has the potential to enrich conventional therapy to improve the treatment of various diseases. Patients that suffer from inflammatory bowel disease, which requires a constant need for medication, have to deal with the adverse effects of repeated application. Natural products such as Epigallocatechin-3-gallate (EGCG) possess the potential to improve symptoms of inflammatory diseases. We investigated the efficacy of EGCG on an inflamed co-culture model simulating IBD and compared it to the efficacies of four commonly applied active pharmaceutical ingredients. EGCG (200 µg/mL) strongly stabilized the TEER value of the inflamed epithelial barrier to 165.7 ± 4.6% after 4 h. Moreover, the full barrier integrity was maintained even after 48 h. This corresponds to the immunosuppressant 6-Mercaptopurin and the biological drug Infliximab. The EGCG treatment significantly decreased the release of the pro-inflammatory cytokines IL-6 (to 0%) and IL-8 (to 14.2%), similar to the effect of the corticosteroid Prednisolone. Therefore, EGCG has a high potential to be deployed as complementary medicine in IBD. In future studies, the improvement of EGCG stability is a key factor in increasing the bioavailability in vivo and fully harnessing the health-improving effects of EGCG.

1 September 2020 in Alternatives to Laboratory Animals
Verified
Journal Article
Open access
PDF file
JMJulia Katharina Metz
Julia Katharina Metz
BWBirgit Wiegand
Birgit Wiegand
SSSabrina Schnur
Sabrina Schnur
KKKatharina Knoth
Katharina Knoth
NSNicole Schneider-Daum
Nicole Schneider-Daum
MHMarius Hittinger
Marius Hittinger
The incidence of inflammatory lung diseases such as acute respiratory distress syndrome (ARDS) remains an important problem, particularly in the present time with the Covid-19 pandemic. However, an adequate in vitro test system to monitor the barrier function of the alveolar epithelium during inflammation and for assessing anti-inflammatory drugs is urgently needed. Therefore, we treated human Alveolar Epithelial Lentivirus-immortalised cells (hAELVi cells) with the pro-inflammatory cytokines TNF-α (25 ng/ml) and IFN-γ (30 ng/ml), in the presence or absence of hydrocortisone (HC). While TNF-α and IFN-γ are known to reduce epithelial barrier properties, HC could be expected to protect the barrier function and result in an anti-inflammatory effect. We investigated the impact of anti-inflammatory/inflammatory treatment on transepithelial electrical resistance (TEER) and the apparent permeability coefficient (P app ) of the low permeability marker sodium fluorescein (NaFlu). After incubating hAELVi cells for 48 hours with a combination of TNF-α and IFN-γ, there was a significant decrease in TEER and a significant increase in the P app . The presence of HC maintained the TEER values and barrier properties, so that no significant P app change was observed. By using hAELVi cells to study anti-inflammatory drugs in vitro, the need for animal experiments could be reduced and pulmonary drug development accelerated.

26 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SLSimone Lichtner
Simone Lichtner
KSKathrin Schunck
Kathrin Schunck
SSSabrina Schnur
Sabrina Schnur
JOJanina Osti
Janina Osti
SDSelina Dannheimer
Selina Dannheimer
MHMarius Hittinger
Marius Hittinger
Inflammatory bowel diseases (IBD) are characterized by chronic intestinal inflammation and epithelial barrier dysfunction, and their treatment relies on anti-inflammatory and immunomodulatory drugs. However, the molecular mechanisms underlying epithelial responses to these therapies remain incompletely understood, particularly at the proteome level. In this study, we applied label-free quantitative proteomics to investigate drug-induced molecular responses in cytokine-stimulated Caco-2 cells treated with mesalazine, prednisolone, or 6-mercaptopurine. We focused on both proteins from lysates and supernatant proteins. Across all treatments, proteomic profiling revealed alterations in pathways related to immune regulation, metabolism, oxidative stress response, and epithelial barrier remodeling. In addition to suppressing inflammatory signaling, drug treatment induced adaptive cellular responses characterized by modulation of energy metabolism, stress resistance and protein biosynthesis. In lysate samples, proteins associated with apoptosis inhibition, immunoproteasome activity, and epithelial integrity were frequently upregulated under treatment, while cytokine-response and inflammatory regulators were reduced. In the supernatants, a general decrease in proteins linked to immune activation, lipid metabolism, and extracellular matrix remodeling was observed, together with barrier-related and wound-healing proteins. Although several barrier-associated proteins were regulated, barrier breakdown in cytokine-stimulated samples could not be directly concluded from proteomic data alone, highlighting the importance of additional readouts. Comparison with previously generated data from monocyte-derived macrophages revealed cell type–specific drug responses and pointed out the metabolic and adaptive nature of epithelial cell regulation. Overall, this study demonstrates that proteomics provides valuable insights into drug-induced epithelial cell adaptation under inflammatory conditions and supports its use as an approach to adding more data to functional assays and improve the relevance of in vitro models for IBD.

2 November 2026 in npj Viruses
Verified
Journal Article
Open access
PDF file
JTJolly Thomas
Jolly Thomas
CNChristoph André Nilius
Christoph André Nilius
LMLeon Matis
Leon Matis
SSSabrina Schnur
Sabrina Schnur
AHAnja Himmelstein
Anja Himmelstein
DLDaniel Christian Lauster
Daniel Christian Lauster
The nasal mucosa is an important site of influenza virus entry and early replication, yet approved antivirals are not designed for nasal delivery. This Review summarizes antiviral strategies suitable for nasal administration and evaluates animal and human-relevant models for their development. We discuss route-specific formulation and regulatory requirements and propose a translational framework integrating in vitro, ex vivo and microphysiological systems with targeted in vivo studies to reduce animal use.